FILANA THERAPEUTICS, INC.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

FLNA$0.45+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Condensed Consolidated Balance Sheets – March 31, 2026 and December 31, 2025

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, In thousands, except share and par value data)

	March 31, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$86,573	$95,502
Prepaid expenses and other current assets	1,391	2,207
Total current assets	87,964	97,709
Property and equipment, net	20,403	20,646
Total assets	$108,367	$118,355
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$39,189	$41,647
Accrued development expense	605	364
Accrued compensation and benefits	246	1,625
Other current liabilities	75	198
Total current liabilities	40,115	43,834
Other non-current liabilities	111	118
Total liabilities	40,226	43,952
Commitments and contingencies (Notes 8, 9 and 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 48,307,896 shares issued and outstanding at March 31, 2026 and December 31, 2025	48	48
Additional paid-in capital	574,508	570,439
Accumulated deficit	(506,415)	(496,084)
Total stockholders' equity	68,141	74,403
Total liabilities and stockholders' equity	$108,367	$118,355

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.